Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant canine thyroid-stimulating hormone (TSH) analog is a recombinant protein developed by Trophogen for veterinary applications, specifically for use in dogs. It is designed to act as an agonist of the thyroid-stimulating hormone receptor (TSHR), mimicking the physiological role of endogenous TSH in stimulating the thyroid gland to produce and release thyroid hormones. This analog is intended for diagnostic purposes, such as the TSH stimulation test used to identify hypothyroidism, and potentially for therapeutic applications. By utilizing recombinant technology, the product aims to provide a consistent and potent alternative to pituitary-derived TSH for veterinary diagnostic testing. The drug is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant canine thyroid-stimulating hormone analog.